SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        Date of Report: October 20, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                   Delaware                          52-1555759
             (State of Incorporation)              (I.R.S. Employer
                                                   Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


Registrant's telephone number, including area code (301) 417-0770


No Exhibits are being filed with this report


CytoGam, RespiGam and Synagis are  registered  trademarks of the Company.
<PAGE>


MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated October 20, 1999:

FOR IMMEDIATE RELEASE

                 MEDIMMUNE REVENUES DOUBLE IN 1999 THIRD QUARTER

     Third Quarter Highlights
     o Revenues Total $48.9 Million
     o Earnings Per Diluted Share Reach $0.08 ($0.10 Before One-Time Item)
     o Sales of Synagis Total $24.4 Million

Gaithersburg,  MD,  October 20, 1999 --  MedImmune,  Inc.  (Nasdaq:  MEDI) today
reported that revenues more than doubled in the 1999 third quarter from the 1998
third  quarter.  Total  revenues  of $48.9  million  in the 1999  third  quarter
included  product sales of $32.2  million and $16.7  million in other  revenues,
including a $15 million milestone payment from Abbott  Laboratories  (NYSE: ABT)
for the European approval of Synagis  (palivizumab) in August. Total revenues of
$23.8 million in the 1998 third quarter  included $22.2 million in product sales
and $1.7 million of other  revenues.  Sales of Synagis in the 1999 third quarter
totaled $24.4 million, a 43-percent  increase over the $17.0 million in sales of
Synagis reported in the 1998 third quarter.  In the 1999 quarter,  international
sales of Synagis totaled $2.3 million. Synagis is marketed for the prevention of
serious respiratory  syncytial virus (RSV) disease in pediatric patients at high
risk for RSV disease,  a seasonal  affliction  that  typically runs from October
through  April  in the  United  States  (see  full  prescribing  information  at
www.medimmune.com/products/synagispi.htm).  The drug was  launched in the United
States in September 1998.

"We are enthused to be starting the second RSV season with Synagis  available to
help  prevent  serious  RSV  disease  in  high-risk  children,"  said  Wayne  T.
Hockmeyer,  Ph.D.,  chairman and chief executive officer.  "In preparing for the
start of the RSV season,  our sales and marketing  organization,  in conjunction
with the Ross  Products  Division  of Abbott  Laboratories,  was busy during the
third quarter educating doctors,  nurses and other caregivers on the benefits of
using Synagis, as well as implementing  reimbursement  programs that should make
it more  financially  convenient  for doctors to provide the drug to appropriate
patients.  We also recently initiated a direct-to-consumer  advertising campaign
aimed at  parents  of  high-risk  children  with the  intent to  increase  their
understanding  of  RSV  disease  and  encourage  discussion  of RSV  with  their
pediatricians.  We believe our  programs  will help us build upon the  successes
experienced during the first season of Synagis sales."

Additional  Third  Quarter Results
Net earnings for the 1999 third quarter were $5.1 million,  or $0.08 per diluted
share,  compared to a net loss of $11.1 million, or $0.21 per share, in the 1998
third  quarter.   Excluding  one-time  expenses   associated  with  the  pending
acquisition  of U.S.  Bioscience,  Inc.  (Amex:  UBS), net earnings for the 1999
third quarter would have been $6.5 million, or $0.10 per diluted share.

<PAGE>

Gross margins of 66 percent in the 1999 quarter reflect  increased  reserves for
CytoGam  Medicaid  rebates  compared to the 69 percent  gross margin in the 1998
third quarter.  Selling,  general and administrative costs rose to $18.3 million
in the 1999 third quarter from $14.3 million in 1998 third quarter, due to costs
associated  with the intended  acquisition of U.S.  Bioscience,  Inc. and higher
promotion-related  expenses  for  Synagis.  Research  and  development  expenses
increased  to $10.2  million in third  quarter  1999 from $5.8  million in third
quarter 1998 due to a larger number of active clinical  trials.  Other operating
expenses  decreased to $4.4  million in third  quarter 1999 from $8.5 million in
third  quarter 1998,  reflecting  increased  production  activity for Synagis at
MedImmune's new manufacturing facility in Frederick, Maryland.

Cash and marketable securities at September 30, 1999 increased to $159.3 million
from $134.9 million at December 31, 1998,  primarily reflecting cash provided by
operations.

Nine-Month  Results
For the nine-month period ending September 30, 1999, MedImmune reported revenues
of $187.9 million, a 74-percent increase over the first nine months of 1998 when
revenues  totaled  $107.8  million.  Revenues in the 1999 period were  primarily
comprised  of $141.9  million in sales of Synagis and $22.3  million of sales of
CytoGam  (Cytomegalovirus  Immune  Globulin  Intravenous  (Human)).  In the 1998
period,  revenues  included  $32.3  million  in sales of  RespiGam  (Respiratory
Syncytial Virus Immune Globulin  Intravenous(Human)),  $23.8 million in sales of
CytoGam,  and $17.0 million in sales of Synagis. As expected since its launch in
the  third  quarter  of 1998,  Synagis  has  largely  replaced  RespiGam  in the
marketplace, causing the shift in revenues.

Net earnings for the first nine months of 1999 were $23.6 million,  or $0.37 per
diluted share,  compared to a net loss of $16.4  million,  or $0.31 per share in
the first nine months of 1998. Gross margins for the nine-month  period improved
to 72 percent in 1999 from 40 percent in 1998, primarily reflecting the shift in
product  mix to  Synagis,  which has a higher  profit  margin  than  CytoGam and
RespiGam. Selling, general and administrative expenses for the first nine months
of 1999 rose to $65.2  million  from $30.4  million in the same  period in 1998,
primarily reflecting increased  promotional and co-promotional  expenses related
to Synagis.  Research  and  development  costs  increased 48 percent in the 1999
period to $27.8 million from $18.8  million in the first three  quarters of 1998
due to the  initiation  of  additional  clinical  studies  for Synagis and other
development-stage  compounds. Other expenses for the 1999 nine-month period were
$16.3  million,  a decrease  of 51  percent  from the  previous  year when other
operating expenses totaled $33.4 million.

Other Third Quarter  Activities
"During the third  quarter,  we focused a great deal of attention on growing our
business,"  commented  Dr.  Hockmeyer.  "We acquired  rights to a new  catalytic
antibody  that we think could  eventually  have  potential  in the  treatment of
cocaine  overdose  and  addiction.  We announced  our  agreement to acquire U.S.
Bioscience, a biotechnology company with a strong focus in the cancer market. We
also announced the European approval of Synagis, raising the number of countries
that have now approved  our drug to 24  worldwide.  Several  more  international
applications are pending and our partner, Abbott International,  is busy rolling
out the  appropriate  programs to advance this  product in the various  targeted
markets.  As you can  see,  our  activities  in the  third  quarter  have  added
substantially  to the growth of our  business  by  expanding  our reach into new
markets,  diversifying  our  pipeline,  and  broadening  our  horizons  into new
therapeutic specialties."

<PAGE>

o    The anti-cocaine  catalytic antibody,  which was exclusively  licensed from
     Columbia University,  is in preclinical research.  Over the next two years,
     MedImmune  expects to humanize and optimize the antibody before moving into
     human clinical testing.
o    On  October  12,  1999,   MedImmune  and  U.S.   Bioscience  filed  an  S-4
     Registration  Statement related to MedImmune's  pending acquisition of U.S.
     Bioscience. Under the terms of the agreement, MedImmune will acquire all of
     U.S. Bioscience's outstanding shares in a tax-free,  stock-for-stock merger
     that is intended to be accounted for as a pooling-of-interests transaction.
     MedImmune hopes to complete the transaction later this year.
o    Synagis is now approved in Argentina, Austria, Australia, Belgium, Brazil,
     Colombia, Denmark,Finland, France, Germany, Greece,Ireland, Italy, Kuwait,
     Luxembourg, Mexico, Netherlands,  New Zealand, Portugal, Spain, Sweden,
     United Kingdom, United States, and Uruguay.  It is also available under
     special permit in Chile.  Currently,  the product is available in all those
     countries  listed above, but at varying degrees of commercial  rollout in
     regards to reimbursement  and pricing that must be handled  differently in
     each country.

Synagis is a  humanized  monoclonal  antibody  marketed  for the  prevention  of
serious lower respiratory tract disease caused by respiratory syncytial virus in
pediatric patients at high risk of RSV disease (see full prescribing information
at  www.medimmune.com/products/synagispi.htm).  CytoGam is an intravenous immune
globulin enriched in antibodies  against  cytomegalovirus  (CMV) and is marketed
for the attenuation of primary CMV disease in  donor-positive/recipient-negative
kidney    transplant    patients   (see   full   prescribing    information   at
www.medimmune.com/products/cytopi1.htm).   RespiGam  is  an  intravenous  immune
globulin  enriched in antibodies  against RSV and is marketed for the prevention
of serious lower  respiratory tract infection caused by RSV in children under 24
months of age with BPD or a history of  premature  birth  (see full  prescribing
information at www.medimmune.com /pro-ducts /resppi.htm).

MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
company's filings with the U.S. Securities and Exchange  Commission.  The FDA is
currently reviewing a supplement to MedImmune's  Biologic License Application to
allow  production  of  Synagis  at  its  Frederick  manufacturing  facility.  No
assurance  can be given that the FDA will  approve the plant to supply  Synagis.
The company has  recently  filed an S-4  Registration  Statement  related to its
pending  acquisition  of U.S.  Bioscience.  There can be no assurance  that this
acquisition  will close,  or that if it closes,  no assurance  can be given that
MedImmune  will   integrate  the   operations  of  the  two  companies   without
encountering  difficulties,  including possible  unanticipated costs, failure to
retain key U.S. Bioscience employees,  or the diversion of management attention.
MedImmune  cautions that RSV disease occurs  primarily during the winter months;
the company believes its operating results will reflect that seasonality for the
foreseeable future.


<PAGE>

                              - Table Follows -
<TABLE>
MedImmune, Inc.
Selected Financial Information
(in thousands, except per share data)

Condensed Statements of Operations (Unaudited)
----------------------------------------------

                                             Three Months Ended      Nine Months Ended
                                                September 30,           September 30,
                                             1999         1998*        1999         1998*
<S>                                         <C>         <C>          <C>         <C>
                                            ---------   ---------    ---------   ---------
Revenues:
Product sales                               $  32,201   $  22,181    $ 167,397   $  73,224
Contracts                                      16,710       1,659       20,474      34,545
                                            ---------   ---------    ---------   ---------
                                               48,911      23,840      187,871     107,769
                                            ---------   ---------    ---------   ---------
Costs and expenses:
Cost of sales                                  10,828       6,903       46,649      43,661
Research and development                       10,214       5,766       27,849      18,761
Selling, administrative and general            18,315      14,286       65,230      30,430
Other operating expenses                        4,429       8,509       16,313      33,447
                                            ---------   ---------    ---------   ---------
                                               43,786      35,464      156,041     126,299
                                            ---------   ---------    ----------  ---------
Interest income, net                            1,788         572        4,718       2,115
                                            ---------   ---------    ---------   ---------
Income (loss) before income taxes               6,913     (11,052)      36,548     (16,415)
Provision for income taxes                      1,774          --       12,935          --
                                            ---------   ---------    ---------   ---------
Net earnings (loss)                         $   5,139   $ (11,052)   $  23,613   $ (16,415)
                                            =========    =========    =========  =========

Basic earnings (loss) per share             $    0.08   $   (0.21)   $    0.41   $   (0.31)
                                            ==========   =========    =========  =========
Shares used in computing basic
earnings (loss) per share                      62,890      53,310       58,041      52,754
                                            =========   =========    =========   =========

Diluted earnings (loss) per share           $    0.08   $   (0.21)   $    0.37   $   (0.31)
                                            =========   =========    =========   =========
Shares used in computing
diluted earnings (loss) per share              67,036      53,310       66,213      52,754
                                            =========   =========    =========   =========

Condensed Balance Sheets
------------------------
                                                               September 30,  December 31,
                                                                    1999         1998
                                                                 ---------    ---------
                                                                 unaudited
<S>                                                              <C>            <C>
Assets:
Cash and marketable securities                                    $ 159,310    $ 134,882
Trade and contract receivables, net                                  23,711       34,837
Inventory, net                                                       28,673       24,709
Deferred taxes, net                                                 108,806       77,518
Property and equipment, net                                          81,575       74,822
Other assets                                                         14,333        6,352
                                                                   ---------    ---------
                                                                  $ 416,408    $ 353,120
                                                                   =========    =========

Liabilities and shareholders' equity:
Accounts payable                                                  $   4,189    $   4,052
Accrued expenses                                                     24,358       33,397
Long term debt                                                       19,695       85,892
Other liabilities                                                    10,822       19,947
Shareholders' equity                                                357,344      209,832
                                                                    ---------    --------
                                                                  $ 416,408    $ 353,120
                                                                    =========    ========
Common shares outstanding                                            63,278       54,655
                                                                    =========    ========
</TABLE>

<PAGE>

*Prior year share and per share  amounts  have been  restated to give effect for
the 2 for 1 stock split on December 31, 1998.


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.




                         MEDIMMUNE, INC.
                         ----------------
                         (Registrant)


Signed By              /s/David M. Mott
October 21, 1999       David M. Mott, Vice Chairman and
                       Chief Financial Officer
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE REVENUES DOUBLE IN 1999 THIRD QUARTER", "secsgml_size_bytes": 18378}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99731715"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        Date of Report: October 20, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

                   Delaware                          52-1555759
             (State of Incorporation)              (I.R.S. Employer
                                                   Identification No.)

                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)

Registrant's telephone number, including area code (301) 417-0770

No Exhibits are being filed with this report

CytoGam, RespiGam and Synagis are  registered  trademarks of the Company.
MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated October 20, 1999:

FOR IMMEDIATE RELEASE

                 MEDIMMUNE REVENUES DOUBLE IN 1999 THIRD QUARTER

     Third Quarter Highlights
     o Revenues Total $48.9 Million
     o Earnings Per Diluted Share Reach $0.08 ($0.10 Before One-Time Item)
     o Sales of Synagis Total $24.4 Million

Gaithersburg,  MD,  October 20, 1999 --  MedImmune,  Inc.  (Nasdaq:  MEDI) today
reported that revenues more than doubled in the 1999 third quarter from the 1998
third  quarter.  Total  revenues  of $48.9  million  in the 1999  third  quarter
included  product sales of $32.2  million and $16.7  million in other  revenues,
including a $15 million milestone payment from Abbott  Laboratories  (NYSE: ABT)
for the European approval of Synagis  (palivizumab) in August. Total revenues of
$23.8 million in the 1998 third quarter  included $22.2 million in product sales
and $1.7 million of other  revenues.  Sales of Synagis in the 1999 third quarter
totaled $24.4 million, a 43-percent  increase over the $17.0 million in sales of
Synagis reported in the 1998 third quarter.  In the 1999 quarter,  international
sales of Synagis totaled $2.3 million. Synagis is marketed for the prevention of
serious respiratory  syncytial virus (RSV) disease in pediatric patients at high
risk for RSV disease,  a seasonal  affliction  that  typically runs from October
through  April  in the  United  States  (see  full  prescribing  information  at
www.medimmune.com/products/synagispi.htm).  The drug was  launched in the United
States in September 1998.

"We are enthused to be starting the second RSV season with Synagis  available to
help  prevent  serious  RSV  disease  in  high-risk  children,"  said  Wayne  T.
Hockmeyer,  Ph.D.,  chairman and chief executive officer.  "In preparing for the
start of the RSV season,  our sales and marketing  organization,  in conjunction
with the Ross  Products  Division  of Abbott  Laboratories,  was busy during the
third quarter educating doctors,  nurses and other caregivers on the benefits of
using Synagis, as well as implementing  reimbursement  programs that should make
it more  financially  convenient  for doctors to provide the drug to appropriate
patients.  We also recently initiated a direct-to-consumer  advertising campaign
aimed at  parents  of  high-risk  children  with the  intent to  increase  their
understanding  of  RSV  disease  and  encourage  discussion  of RSV  with  their
pediatricians.  We believe our  programs  will help us build upon the  successes
experienced during the first season of Synagis sales."

Additional  Third  Quarter Results
Net earnings for the 1999 third quarter were $5.1 million,  or $0.08 per diluted
share,  compared to a net loss of $11.1 million, or $0.21 per share, in the 1998
third  quarter.   Excluding  one-time  expenses   associated  with  the  pending
acquisition  of U.S.  Bioscience,  Inc.  (Amex:  UBS), net earnings for the 1999
third quarter would have been $6.5 million, or $0.10 per diluted share.
Gross margins of 66 percent in the 1999 quarter reflect  increased  reserves for
CytoGam  Medicaid  rebates  compared to the 69 percent  gross margin in the 1998
third quarter.  Selling,  general and administrative costs rose to $18.3 million
in the 1999 third quarter from $14.3 million in 1998 third quarter, due to costs
associated  with the intended  acquisition of U.S.  Bioscience,  Inc. and higher
promotion-related  expenses  for  Synagis.  Research  and  development  expenses
increased  to $10.2  million in third  quarter  1999 from $5.8  million in third
quarter 1998 due to a larger number of active clinical  trials.  Other operating
expenses  decreased to $4.4  million in third  quarter 1999 from $8.5 million in
third  quarter 1998,  reflecting  increased  production  activity for Synagis at
MedImmune's new manufacturing facility in Frederick, Maryland.

Cash and marketable securities at September 30, 1999 increased to $159.3 million
from $134.9 million at December 31, 1998,  primarily reflecting cash provided by
operations.

Nine-Month  Results
For the nine-month period ending September 30, 1999, MedImmune reported revenues
of $187.9 million, a 74-percent increase over the first nine months of 1998 when
revenues  totaled  $107.8  million.  Revenues in the 1999 period were  primarily
comprised  of $141.9  million in sales of Synagis and $22.3  million of sales of
CytoGam  (Cytomegalovirus  Immune  Globulin  Intravenous  (Human)).  In the 1998
period,  revenues  included  $32.3  million  in sales of  RespiGam  (Respiratory
Syncytial Virus Immune Globulin  Intravenous(Human)),  $23.8 million in sales of
CytoGam,  and $17.0 million in sales of Synagis. As expected since its launch in
the  third  quarter  of 1998,  Synagis  has  largely  replaced  RespiGam  in the
marketplace, causing the shift in revenues.

Net earnings for the first nine months of 1999 were $23.6 million,  or $0.37 per
diluted share,  compared to a net loss of $16.4  million,  or $0.31 per share in
the first nine months of 1998. Gross margins for the nine-month  period improved
to 72 percent in 1999 from 40 percent in 1998, primarily reflecting the shift in
product  mix to  Synagis,  which has a higher  profit  margin  than  CytoGam and
RespiGam. Selling, general and administrative expenses for the first nine months
of 1999 rose to $65.2  million  from $30.4  million in the same  period in 1998,
primarily reflecting increased  promotional and co-promotional  expenses related
to Synagis.  Research  and  development  costs  increased 48 percent in the 1999
period to $27.8 million from $18.8  million in the first three  quarters of 1998
due to the  initiation  of  additional  clinical  studies  for Synagis and other
development-stage  compounds. Other expenses for the 1999 nine-month period were
$16.3  million,  a decrease  of 51  percent  from the  previous  year when other
operating expenses totaled $33.4 million.

Other Third Quarter  Activities
"During the third  quarter,  we focused a great deal of attention on growing our
business,"  commented  Dr.  Hockmeyer.  "We acquired  rights to a new  catalytic
antibody  that we think could  eventually  have  potential  in the  treatment of
cocaine  overdose  and  addiction.  We announced  our  agreement to acquire U.S.
Bioscience, a biotechnology company with a strong focus in the cancer market. We
also announced the European approval of Synagis, raising the number of countries
that have now approved  our drug to 24  worldwide.  Several  more  international
applications are pending and our partner, Abbott International,  is busy rolling
out the  appropriate  programs to advance this  product in the various  targeted
markets.  As you can  see,  our  activities  in the  third  quarter  have  added
substantially  to the growth of our  business  by  expanding  our reach into new
markets,  diversifying  our  pipeline,  and  broadening  our  horizons  into new
therapeutic specialties."
o    The anti-cocaine  catalytic antibody,  which was exclusively  licensed from
     Columbia University,  is in preclinical research.  Over the next two years,
     MedImmune  expects to humanize and optimize the antibody before moving into
     human clinical testing.
o    On  October  12,  1999,   MedImmune  and  U.S.   Bioscience  filed  an  S-4
     Registration  Statement related to MedImmune's  pending acquisition of U.S.
     Bioscience. Under the terms of the agreement, MedImmune will acquire all of
     U.S. Bioscience's outstanding shares in a tax-free,  stock-for-stock merger
     that is intended to be accounted for as a pooling-of-interests transaction.
     MedImmune hopes to complete the transaction later this year.
o    Synagis is now approved in Argentina, Austria, Australia, Belgium, Brazil,
     Colombia, Denmark,Finland, France, Germany, Greece,Ireland, Italy, Kuwait,
     Luxembourg, Mexico, Netherlands,  New Zealand, Portugal, Spain, Sweden,
     United Kingdom, United States, and Uruguay.  It is also available under
     special permit in Chile.  Currently,  the product is available in all those
     countries  listed above, but at varying degrees of commercial  rollout in
     regards to reimbursement  and pricing that must be handled  differently in
     each country.

Synagis is a  humanized  monoclonal  antibody  marketed  for the  prevention  of
serious lower respiratory tract disease caused by respiratory syncytial virus in
pediatric patients at high risk of RSV disease (see full prescribing information
at  www.medimmune.com/products/synagispi.htm).  CytoGam is an intravenous immune
globulin enriched in antibodies  against  cytomegalovirus  (CMV) and is marketed
for the attenuation of primary CMV disease in  donor-positive/recipient-negative
kidney    transplant    patients   (see   full   prescribing    information   at
www.medimmune.com/products/cytopi1.htm).   RespiGam  is  an  intravenous  immune
globulin  enriched in antibodies  against RSV and is marketed for the prevention
of serious lower  respiratory tract infection caused by RSV in children under 24
months of age with BPD or a history of  premature  birth  (see full  prescribing
information at www.medimmune.com /pro-ducts /resppi.htm).

MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
company's filings with the U.S. Securities and Exchange  Commission.  The FDA is
currently reviewing a supplement to MedImmune's  Biologic License Application to
allow  production  of  Synagis  at  its  Frederick  manufacturing  facility.  No
assurance  can be given that the FDA will  approve the plant to supply  Synagis.
The company has  recently  filed an S-4  Registration  Statement  related to its
pending  acquisition  of U.S.  Bioscience.  There can be no assurance  that this
acquisition  will close,  or that if it closes,  no assurance  can be given that
MedImmune  will   integrate  the   operations  of  the  two  companies   without
encountering  difficulties,  including possible  unanticipated costs, failure to
retain key U.S. Bioscience employees,  or the diversion of management attention.
MedImmune  cautions that RSV disease occurs  primarily during the winter months;
the company believes its operating results will reflect that seasonality for the
foreseeable future.
- Table Follows -

MedImmune, Inc.
Selected Financial Information
(in thousands, except per share data)

Condensed Statements of Operations (Unaudited)
----------------------------------------------

                                             Three Months Ended      Nine Months Ended
                                                September 30,           September 30,
                                             1999         1998*        1999         1998*
---------   ---------    ---------   ---------
Revenues:
Product sales                               $  32,201   $  22,181    $ 167,397   $  73,224
Contracts                                      16,710       1,659       20,474      34,545
                                            ---------   ---------    ---------   ---------
                                               48,911      23,840      187,871     107,769
                                            ---------   ---------    ---------   ---------
Costs and expenses:
Cost of sales                                  10,828       6,903       46,649      43,661
Research and development                       10,214       5,766       27,849      18,761
Selling, administrative and general            18,315      14,286       65,230      30,430
Other operating expenses                        4,429       8,509       16,313      33,447
                                            ---------   ---------    ---------   ---------
                                               43,786      35,464      156,041     126,299
                                            ---------   ---------    ----------  ---------
Interest income, net                            1,788         572        4,718       2,115
                                            ---------   ---------    ---------   ---------
Income (loss) before income taxes               6,913     (11,052)      36,548     (16,415)
Provision for income taxes                      1,774          --       12,935          --
                                            ---------   ---------    ---------   ---------
Net earnings (loss)                         $   5,139   $ (11,052)   $  23,613   $ (16,415)
                                            =========    =========    =========  =========

Basic earnings (loss) per share             $    0.08   $   (0.21)   $    0.41   $   (0.31)
                                            ==========   =========    =========  =========
Shares used in computing basic
earnings (loss) per share                      62,890      53,310       58,041      52,754
                                            =========   =========    =========   =========

Diluted earnings (loss) per share           $    0.08   $   (0.21)   $    0.37   $   (0.31)
                                            =========   =========    =========   =========
Shares used in computing
diluted earnings (loss) per share              67,036      53,310       66,213      52,754
                                            =========   =========    =========   =========

Condensed Balance Sheets
------------------------
                                                               September 30,  December 31,
                                                                    1999         1998
                                                                 ---------    ---------
                                                                 unaudited
Assets:
Cash and marketable securities                                    $ 159,310    $ 134,882
Trade and contract receivables, net                                  23,711       34,837
Inventory, net                                                       28,673       24,709
Deferred taxes, net                                                 108,806       77,518
Property and equipment, net                                          81,575       74,822
Other assets                                                         14,333        6,352
                                                                   ---------    ---------
                                                                  $ 416,408    $ 353,120
                                                                   =========    =========

Liabilities and shareholders' equity:
Accounts payable                                                  $   4,189    $   4,052
Accrued expenses                                                     24,358       33,397
Long term debt                                                       19,695       85,892
Other liabilities                                                    10,822       19,947
Shareholders' equity                                                357,344      209,832
                                                                    ---------    --------
                                                                  $ 416,408    $ 353,120
                                                                    =========    ========
Common shares outstanding                                            63,278       54,655
                                                                    =========    ========
*Prior year share and per share  amounts  have been  restated to give effect for
the 2 for 1 stock split on December 31, 1998.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                         MEDIMMUNE, INC.
                         ----------------
                         (Registrant)

Signed By              /s/David M. Mott
October 21, 1999       David M. Mott, Vice Chairman and
                       Chief Financial Officer